The physiological, cellular, and/or genetic basis of a disease is studied to identify potential therapeutic targets. 



Once a potential target has been identified, researchers will then screen thousands of APIs, excipients and/or formulations for potential candidates that act on this target.


After early testing, however, only a small number of compounds look promising and call for further study. 


We are in the age of cell therapy and gene therapy with bioprocessing being a key element. Being able to affect disease at the molecular level is the key, and nanomedicine is a fundamental technology for ushering in the next wave of genetic and molecularly targeted therapeutics.

The NanoAssemblr® Product Suite and Formulation Solutions

NanoAssemblr Spark


The NanoAssemblr® Spark™ produces microlitre volumes of nanomedicines for discovery research.

NanoAssemblr Benchtop



The NanoAssemblr® Ignite manufactures 1 – 15 mL of nanomedicine per run for nanomedicine development programs.

Formulation Solution Experts




To rapidly reach the formulation proof of concept stage PNI offers highly qualified scientist with extensive formulation development experience through our Formulation Solutions Team.                                                                                                                                           


At every step, our multidisciplinary experts will partner with you to build affirm scientific foundation for the work ahead.

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch

Resource Center


September 01, 2022

Scale Up Genome Editing of CAR T Cells using Lipid Nanoparticles

Read More 阅读更多 PDF

Application Note

March 15, 2022

Genome Editing of Human Primary T Cells with Lipid Nanoparticles

Read More 阅读更多 PDF

Publication - Abstract

July 01, 2020

Journal of Controlled Release

Delivery of Self-amplifying mRNA Vaccines by Cationic Lipid Nanoparticles: The Impact of Cationic Lipid Select...

G. Lou, G. Anderluzzi, S.T. Schmidt, S. Woods, S. Gallorini, M. Brazzoli, F. Giusti, I. F...

Read More 阅读更多

Publication - Abstract

May 08, 2020


Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines

G. Anderluzzi, G. Lou, S. Gallorini, M. Brazzoli, R. Johnson, D.T. O'Hagan, B.C. Baudner a...

Read More 阅读更多

Publication - Abstract

April 02, 2020

Journal of Controlled Release

Design of a Novel Vaccine Nanotechnology-based Delivery System Comprising CpGODN-protein Conjugate Anchored to...

D. Chatzikleanthous, S.T. Schmidt, G. Buffi, I. Paciello, R. Cunliffe, F. Carboni, M.R. Ro...

Read More 阅读更多

Publication - Abstract

December 31, 2019


Investigating Prime-Pull Vaccination through a Combination of Parenteral Vaccination and Intranasal Boosting

C.B. Roces, M.T. Hussain, S.T. Schmidt, D. Christensen and Y. Perrie

Read More 阅读更多
Resource Center 资源中心